title: Effects of Chungkookjang supplementation on obesity and atherosclerotic indices in overweight/obese subjects: a 12-week, randomized, double-blind, placebo-controlled clinical trial.
abstract: This study was designed to investigate the anti-obesity and anti-atherosclerotic effects of supplementation with Chungkookjang (CKJ), a traditional fermented soybean food, in overweight/obese subjects. The study was a 12-week, randomized, double-blind, placebo-controlled clinical trial followed by a 3-week screening period. Overweight/obese subjects (both groups having a body mass index ≥23 kg/m(2) and waist hip ratio of ≥0.90 for men and ≥0.85 for women) who were not diagnosed with any disease were included in this study. Sixty subjects were randomly divided into a CKJ (n=30, 26 g/day) or placebo (n=30) group. During the 12-week intervention period, subjects were asked to maintain their usual diet and activity and not to take any functional foods or dietary supplements. Anthropometric parameters, abdominal fat distribution by computerized tomography, and blood parameters (lipid profile, atherosclerotic indices) before and after the 12-week intervention period were measured. Fifty-five subjects (29 CKJ group, 26 placebo group) finished the study. After the 12 weeks of supplementation, subjects in the CKJ group showed a significant improvement in apolipoprotein B (P<.05) compared with the placebo group. Visceral fat areas by computerized tomography scans and apolipoprotein B/apolipoprotein A1 showed a tendency to decrease in the CKJ group, but there were no significant differences between the CKJ and placebo groups. These results suggested that CKJ supplementation has potential anti-atherosclerotic effects that might be more pronounced when combined with lifestyle modification.
authors: Department of Food Science and Human Nutrition, Research Institute of Human Ecology, Chonbuk National University, Jeonju, Jeonbuk, Republic of Korea.
authors: Hyang-Im
authors: HI
authors: Back
authors: Soo-Ran
authors: SR
authors: Kim
authors: Ji-Ae
authors: JA
authors: Yang
authors: Min-Gul
authors: MG
authors: Kim
authors: Soo-Wan
authors: SW
authors: Chae
authors: Youn-Soo
authors: YS
authors: Cha
mesh_terms: D050153:Abdominal Fat / Q000187:drug effects; D000328:Adult; D000886:Anthropometry; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D016632:Apolipoprotein A-I / Q000032:analysis / Q000378:metabolism; D001055:Apolipoproteins B / Q000032:analysis / Q000378:metabolism; D050197:Atherosclerosis / Q000188:drug therapy*; D050218:Body Fat Distribution; D015992:Body Mass Index; D008076:Cholesterol, HDL / Q000097:blood; D008078:Cholesterol, LDL / Q000097:blood; D019587:Dietary Supplements; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000008:administration & dosage*; D008019:Life Style; D008297:Male; D009765:Obesity / Q000188:drug therapy*; D057566:Self Report; D030262:Soybean Proteins / Q000008:administration & dosage*
chemical_list: D019440:Anti-Obesity Agents; D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D007529:Isoflavones; D030262:Soybean Proteins; C525760:chungkookjang